ABT · Abbott Laboratories - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.16B | - | $11.37B | $11.14B | $10.36B | - | $10.63B | $10.38B | $9.96B | - |
| Cost of Revenue | $4.89B | - | $5.08B | $4.85B | $4.47B | - | $4.70B | $4.60B | $4.46B | - |
| Gross Profit | $6.27B | - | $6.29B | $6.29B | $5.89B | - | $5.94B | $5.77B | $5.50B | - |
| R&D | $767.00M | - | $766.00M | $725.00M | $716.00M | - | $713.00M | $698.00M | $684.00M | - |
| SG&A | $3.74B | - | $3.05B | $3.09B | $3.06B | - | $2.90B | $2.94B | $2.96B | - |
| Total Operating Expenses | $9.82B | - | $9.31B | $9.09B | $8.66B | - | $8.78B | $8.71B | $8.58B | - |
| D&A | $381.00M | - | $331.00M | $334.00M | $336.00M | - | - | - | $333.00M | - |
| Operating Income | $1.34B | - | $2.06B | $2.05B | $1.69B | - | $1.86B | $1.67B | $1.39B | - |
| Interest Expense | $174.00M | - | $121.00M | $121.00M | $141.00M | - | $166.00M | $140.00M | $141.00M | - |
| Income Tax | $372.00M | - | $536.00M | $371.00M | $453.00M | - | $294.00M | $305.00M | $211.00M | - |
| Net Income | $1.08B | - | $1.64B | $1.78B | $1.32B | - | $1.65B | $1.30B | $1.23B | - |
| EPS - Basic | $0.62 | - | $0.94 | $1.02 | $0.76 | - | $0.94 | $0.74 | $0.70 | - |
| EPS - Diluted | $0.61 | - | $0.94 | $1.01 | $0.76 | - | $0.94 | $0.74 | $0.70 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.80B | $8.52B | $7.51B | $6.95B | $6.53B | $7.62B | $7.56B | $6.99B | $6.28B | $6.90B |
| Accounts Receivable | $8.21B | $7.93B | $8.14B | $7.97B | $7.33B | $6.92B | $7.05B | $6.85B | $6.61B | $6.57B |
| Inventory | $6.99B | $6.49B | $6.71B | $6.95B | $6.64B | $6.19B | $6.81B | $6.81B | $6.83B | $6.57B |
| Accounts Payable | $4.68B | $4.24B | $4.12B | $4.31B | $4.21B | $4.20B | $4.03B | $4.13B | $4.18B | $4.29B |
| Current Assets | $25.51B | $26.00B | $24.84B | $24.47B | $23.15B | $23.66B | $23.80B | $23.12B | $22.38B | $22.67B |
| Total Assets | $110.43B | $86.71B | $84.18B | $84.00B | $81.45B | $81.41B | $74.36B | $73.02B | $72.47B | $73.21B |
| Current Liabilities | $18.38B | $16.50B | $14.58B | $13.44B | $13.00B | $14.16B | $14.90B | $13.76B | $14.02B | $13.84B |
| Long-term Debt | $29.64B | $9.90B | $11.60B | $12.93B | $12.74B | $12.63B | $12.82B | $13.14B | $12.58B | $13.60B |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $52.06B | $52.13B | $50.95B | $50.56B | $48.81B | $47.66B | $39.80B | $39.32B | $38.81B | $38.60B |
| Retained Earnings | $49.96B | $49.78B | $49.10B | $48.47B | $47.72B | $47.26B | $39.06B | $38.35B | $38.01B | $37.55B |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.31B | - | - | - | $1.42B | - | - | - | $1.02B | - |
| Investing Cash Flow | ($20.32B) | - | - | - | ($470.00M) | - | - | - | ($425.00M) | - |
| Financing Cash Flow | $17.31B | - | - | - | ($2.06B) | - | - | - | ($1.18B) | - |
| CapEx | $399.00M | - | - | - | $484.00M | - | - | - | $398.00M | - |
| Free Cash Flow | $916.00M | - | - | - | $933.00M | - | - | - | $627.00M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 56.2% | - | 55.4% | 56.4% | 56.9% | - | 55.8% | 55.6% | 55.2% | - |
| Operating margin | 12.0% | - | 18.1% | 18.4% | 16.3% | - | 17.5% | 16.1% | 13.9% | - |
| EBITDA margin | 15.5% | - | 21.0% | 21.4% | 19.6% | - | - | - | 17.3% | - |
| Net margin | 9.6% | - | 14.5% | 16.0% | 12.8% | - | 15.5% | 12.5% | 12.3% | - |
| Free cash flow margin | 8.2% | - | - | - | 9.0% | - | - | - | 6.3% | - |
| FCF / Net income | 0.85 | - | - | - | 0.70 | - | - | - | 0.51 | - |
| R&D / Revenue | 6.9% | - | 6.7% | 6.5% | 6.9% | - | 6.7% | 6.7% | 6.9% | - |
| SG&A / Revenue | 33.5% | - | 26.8% | 27.7% | 29.6% | - | 27.2% | 28.3% | 29.7% | - |
| Effective tax rate | 25.7% | - | 24.6% | 17.3% | 25.5% | - | 15.2% | 19.0% | 14.7% | - |
| Return on assets | 1.0% | - | 2.0% | 2.1% | 1.6% | - | 2.2% | 1.8% | 1.7% | - |
| Return on equity | 2.1% | - | 3.2% | 3.5% | 2.7% | - | 4.1% | 3.3% | 3.2% | - |
| Return on invested capital | 1.2% | - | 2.5% | 2.7% | 2.0% | - | 3.0% | 2.6% | 2.3% | - |
| Liquidity | ||||||||||
| Current ratio | 1.39 | 1.58 | 1.70 | 1.82 | 1.78 | 1.67 | 1.60 | 1.68 | 1.60 | 1.64 |
| Quick ratio | 1.01 | 1.18 | 1.24 | 1.30 | 1.27 | 1.23 | 1.14 | 1.18 | 1.11 | 1.16 |
| Cash ratio | 0.37 | 0.52 | 0.52 | 0.52 | 0.50 | 0.54 | 0.51 | 0.51 | 0.45 | 0.50 |
| Leverage | ||||||||||
| Debt / Equity | 0.57 | 0.19 | 0.23 | 0.26 | 0.26 | 0.26 | 0.32 | 0.33 | 0.32 | 0.35 |
| Debt / Assets | 0.27 | 0.11 | 0.14 | 0.15 | 0.16 | 0.16 | 0.17 | 0.18 | 0.17 | 0.19 |
| Debt / EBITDA | 17.17 | - | 4.86 | 5.42 | 6.28 | - | - | - | 7.32 | - |
| Interest coverage | 7.7x | - | 17.0x | 17.0x | 12.0x | - | 11.2x | 11.9x | 9.8x | - |
| Equity multiplier | 2.12 | 1.66 | 1.65 | 1.66 | 1.67 | 1.71 | 1.87 | 1.86 | 1.87 | 1.90 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.10 | - | 0.14 | 0.13 | 0.13 | - | 0.14 | 0.14 | 0.14 | - |
| Inventory turnover | 0.70 | - | 0.76 | 0.70 | 0.67 | - | 0.69 | 0.68 | 0.65 | - |
| Days sales outstanding | 268d | - | 261d | 261d | 258d | - | 242d | 241d | 242d | - |
| Days inventory outstanding | 522d | - | 482d | 523d | 542d | - | 529d | 540d | 558d | - |
| Days payable outstanding | 349d | - | 297d | 324d | 344d | - | 313d | 327d | 342d | - |
| Cash conversion cycle | 441d | - | 447d | 460d | 456d | - | 458d | 454d | 459d | - |
| Valuation | ||||||||||
| P / E | 168.3x | - | 142.5x | 134.7x | 174.5x | - | 121.3x | 140.4x | 162.4x | - |
| P / B | 3.4x | - | 4.6x | 4.7x | 4.7x | - | 5.0x | 4.6x | 5.1x | - |
| P / S | 16.1x | - | 20.6x | 21.4x | 22.4x | - | 18.7x | 17.5x | 20.0x | - |
| EV / EBITDA | 117.2x | - | 99.8x | 102.3x | 117.3x | - | - | - | 119.3x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 7.8% | - | 6.9% | 7.4% | 4.0% | - | 4.9% | 4.0% | 2.2% | - |
| Revenue CAGR (3y) | 4.6% | - | 3.0% | -0.3% | -4.5% | - | -0.9% | 0.5% | -1.6% | - |
| Revenue CAGR (5y) | 1.3% | - | 5.1% | 8.7% | 6.0% | - | 5.7% | 5.4% | 5.7% | - |
| Gross profit growth (YoY) | 6.5% | - | 6.0% | 8.9% | 7.1% | - | 7.2% | 5.1% | 1.6% | - |
| Operating income growth (YoY) | -20.6% | - | 10.7% | 22.9% | 22.2% | - | 12.9% | 8.2% | -8.2% | - |
| Net income growth (YoY) | -18.7% | - | -0.1% | 36.6% | 8.2% | - | 14.6% | -5.3% | -7.1% | - |
| EPS growth (YoY) | -19.7% | - | 0.0% | 36.5% | 8.6% | - | 14.6% | -5.1% | -6.7% | - |
| EPS CAGR (3y) | -6.7% | - | 5.1% | -4.0% | -17.8% | - | -7.0% | 3.9% | -11.2% | - |
| EPS CAGR (5y) | -9.4% | - | 6.4% | 27.5% | 19.6% | - | 12.1% | 5.7% | 13.0% | - |
| FCF growth (YoY) | -1.8% | - | - | - | 48.8% | - | - | - | -17.8% | - |
| FCF CAGR (5y) | -16.4% | - | - | - | 21.3% | - | - | - | 10.7% | - |
| Book value growth (YoY) | 6.7% | 9.4% | 28.0% | 28.6% | 25.8% | 23.5% | 6.2% | 5.8% | 4.9% | 5.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$16.15B totalDiagnostic Products$5.36B · 33.2%
Established Pharmaceutical Products$4.17B · 25.8%
Nutritional Products$3.97B · 24.6%
Medical Devices$2.65B · 16.4%
Product / service
$297.00M totalCOVID19 Testing$297.00M · 100.0%
Geographic
$33.53B totalAll Other Countries$15.98B · 47.7%
Non Us$4.17B · 12.4%
DE$2.76B · 8.2%
US$2.16B · 6.4%
CN$1.91B · 5.7%
CH$1.87B · 5.6%
IN$1.87B · 5.6%
JP$1.48B · 4.4%
GB$1.34B · 4.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ABBOTT LABORATORIES against the 5 most active filers in the same SIC group.
Dividends
$2.44/share trailing 12 months · +7.0% YoY
| Ex-date | Per share |
|---|---|
| Apr 15, 2026 | $0.6300 |
| Jan 15, 2026 | $0.6300 |
| Oct 15, 2025 | $0.5900 |
| Jul 15, 2025 | $0.5900 |
| Apr 15, 2025 | $0.5900 |
| Jan 15, 2025 | $0.5900 |
| Oct 15, 2024 | $0.5500 |
| Jul 15, 2024 | $0.5500 |
| Apr 12, 2024 | $0.5500 |
| Jan 11, 2024 | $0.5500 |
| Oct 12, 2023 | $0.5100 |
| Jul 13, 2023 | $0.5100 |
| Apr 13, 2023 | $0.5100 |
| Jan 12, 2023 | $0.5100 |
| Oct 13, 2022 | $0.4700 |
| Jul 14, 2022 | $0.4700 |
| Apr 13, 2022 | $0.4700 |
| Jan 13, 2022 | $0.4700 |
| Oct 14, 2021 | $0.4500 |
| Jul 14, 2021 | $0.4500 |
| Apr 14, 2021 | $0.4500 |
| Jan 14, 2021 | $0.4500 |
| Oct 14, 2020 | $0.3600 |
| Jul 14, 2020 | $0.3600 |